Literature DB >> 10349543

Malignant melanoma: a clinical review.

T J Brown, B R Nelson.   

Abstract

The incidence of cutaneous malignant melanoma is increasing at an alarming rate. It is projected that Americans born in the year 2000 will have a 1 in 75 lifetime risk of developing melanoma. Long-term survival for patients with metastatic disease is only 5% and approximately 15% of patients diagnosed with melanoma eventually die from their disease. Conversely, the prognosis for early disease is excellent and often simple surgical excision is curative. It is therefore crucial that the practicing physician becomes familiar with all of the clinical and histologic presentations in order to ensure an accurate and prompt diagnosis. This, in turn, should lead to earlier detection and a more favorable prognosis.

Entities:  

Mesh:

Year:  1999        PMID: 10349543

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  4 in total

1.  Stress-responsive JNK mitogen-activated protein kinase mediates aspirin-induced suppression of B16 melanoma cellular proliferation.

Authors:  Orly Ordan; Ronit Rotem; Ilona Jaspers; Eliezer Flescher
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

2.  Massive bilateral adrenal gland metastases from melanoma diagnosed by F18-FDG-PET/CT.

Authors:  Francesco Bertagna; Giorgio Biasiotto; Carlo Rodella; Thomas Werner; Raffaele Giubbini; Abass Alavi
Journal:  Jpn J Radiol       Date:  2009-11-27       Impact factor: 2.374

3.  Cosmetic outcomes following head and neck melanoma reconstruction: The patient's perspective.

Authors:  Donald Buck; Vinay Rawlani; Jeffrey Wayne; Gregory A Dumanian; Thomas A Mustoe; Neil A Fine; Robert Galiano; John Ys Kim
Journal:  Can J Plast Surg       Date:  2012

4.  Antitumor agent 25-epi Ritterostatin GN1N induces endoplasmic reticulum stress and autophagy mediated cell death in melanoma cells.

Authors:  Kausar Begam Riaz Ahmed; Ananda Kumar Kanduluru; Li Feng; Philip L Fuchs; Peng Huang
Journal:  Int J Oncol       Date:  2017-04-03       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.